In this community, professionals share information regarding the clinical, programmatic and community-oriented aspects of early diagnosis, treatment and prevention of multi-drug-resistant tuberculosis (MDR-TB). Members also use this forum to promote universal access to quality care for MDR-TB.

Community moderators

Masoud Dara, MD
WHO Europe - EURO
Christopher Gilpin, PhD, MPH
World Health Organization - WHO
Dylan Tierney
Brigham and Women's Hospital, Division of Global Health Equity

Recent community activity

Limit of detection for HAIN

Kathleen England replied

Dear Ranjan, From the package insert HAIN MTBDRplus Version 2.0: Analytical Sensitivity (p.11)…”For the determination of analytical sensitivity of the GenoType MTBDRplus, ten replicates of MTBC-negative sputum samples were spiked with four BCG culture dilutions (1000, 500, 200, 160 and 100 bacteria/ml, respectively), extracted once using the GenoLyse @ kit ... read more

Updated: 26 Aug, 2016
Reply: 1

MGIT DST - YES or NO ?

Kathleen England replied

Dear Monica, There are several reasons for TTP <4 days. a) large number of mycobacterium in the sample (SS grade high positivity) b) Non TB mycobacterium present in patient sample (fast growing NTM) c) Mixed sample NTM and TB bacilli (NTM outgrows the TB bacilli) - You must confirm MTB ... read more

Updated: 26 Aug, 2016
Replies: 4

Number of mutations detected

Kathleen England replied

The Xpert MTB/RIF assay will detect all mutations within the rpoB region. Not all of these mutations cause resistance. These are commonly referred to as silent mutations. Silent mutations observed: F506, T508, Q510, L511, Q513, F514, T525, A532, L533, P535 Mutations found in rpoB region: (Insertions , Deletions, and SNPs) ... read more

Updated: 26 Aug, 2016
Reply: 1

Without Success in India, We'll Never Control Drug-Resistant Tuberculosis Anywhere

Himanshu Vashistha replied

Dear Dr. Pai, Thanks for the information, i also in accordance with the context mentioned. read more

Updated: 26 Aug, 2016
Reply: 1

New community members

User Photo

Ntiense Umoette

Affiliated Organizations

Hospital

Work Locations

Nigeria

User Photo

Judy Stone

Affiliated Organizations

Forbes

Work Locations

United States

tdivala's Profile Image

Titus Divala

Titus Divala is a young physician clinical investigator with a long term goal of becoming a clinical trials expert in infectious diseases affecting vulnerable populations of sub Saharan Africa. His main motivation for doing clinical research is Malawi’s high disease burden which he believes can be solved by generating and implementing high quality locally relevant evidence. He works in a center of excellence in malaria research where he is a site investigator two large clinical trials and several cohort studies in malaria, HIV, maternal and child health. He holds a medical degree (MBBS) and a Master of Public Health (specialization: Epidemiology) from University of Malawi, and a Master of Science in Epidemiology and preventive medicine (specialization: clinical research) from University of Maryland, Baltimore.

Affiliated Organizations

University of Malawi, College of Medicine

Work Locations

Malawi